- Open Access
Targeting fragile X
© BioMed Central Ltd 2002
- Published: 25 April 2002
Ten years after the identification of the gene responsible for fragile X syndrome, recent studies have revealed a list of mRNAs bound by the fragile X gene product and have identified specific sequences required for the interaction between the fragile X protein and its targets. These results are a breakthrough in understanding why absence of the fragile X protein leads to mental retardation.
- Nuclear Export Signal
- FMR1 Gene
- UniGene Database
- FMR1 mRNA
- TIGR Gene Index
With a prevalence of 1 in 5,000, fragile X syndrome is the most common form of hereditary mental retardation . Patients suffer from mild to severe mental retardation, mild facial dismorphologies and macroorchidism (enlarged testicles). In addition, behavioral problems like autism and hyperactivity may be associated with the syndrome . In 1991, defects in the FMR1 gene (fragile X mental retardation gene 1) were identified as the cause of the syndrome . An expansion of a CGG repeat in the 5' untranslated region (UTR) of the FMR1 gene causes transcriptional silencing, resulting in absence of the fragile X protein, FMRP. It was soon discovered that FMRP can bind RNA and plays a role in the transport of mRNAs from the nucleus to ribosomes. Several recent studies [4,5,6] have provided new insights into the motifs responsible for RNA binding and revealed a list of mRNA targets bound by FMRP.
The FMR1 gene is ubiquitously expressed, with particularly high expression in neurons but barely detectable expression in glia . The FMR1 gene product can be up to 631 amino acids long and has five functional domains: two types of RNA-binding structures, namely two KH domains (KH denotes heterogeneous nuclear ribonucleoprotein K homology) and an RGG box (containing repeats of an Arg-Gly-Gly motif - RGG, in the single-letter amino-acid code); a nuclear localization signal (NLS); a nuclear export signal (NES); and two coiled-coil domains. FMRP is predominantly cytoplasmic but shuttles between the cytoplasm and nucleus, a process mediated by the nuclear import and nuclear export signals. FMRP can bind 4% of all brain mRNAs, including its own mRNA, presumably with the aid of its RNA-binding domains . In the nucleus, the FMRP protein forms messenger ribonucleoprotein (mRNP) precursor particles along with other proteins, including nucleolin (which is known to shuttle between the nucleus and cytoplasm) and the fragile X-related proteins FXR1P and FXR2P [9,10]. The FXR1 and FXR2 genes are autosomal paralogs of FMR1, and both gene products have high overall sequence similarity to FMRP, especially within the functional domains . The FMRP-mRNP particles are transported out of the nucleus into the cytoplasm and to actively translating ribosomes [12,13]. It has been hypothesized that, in neurons, FMRP transports specific mRNAs along the dendrites towards actively translating ribosomes near the synapses. Which neuronal RNA targets are bound and why absence of the FMRP protein causes mental retardation remained unknown until recently, however.
Initially, the KH domains were thought to be crucial for the function of FMRP, because an exceptional patient had been described with a point mutation (Ile304 → Asn) in the second KH domain . This patient had a more severe phenotype than any other patient lacking FMRP, including profound mental retardation and excessive macroorchidism. Experiments in vitro demonstrated that the FMRP KH domains interact with high affinity with various mRNAs, including those of FXR1 and FXR2 [11,15]. FMRP is able to suppress translation of mRNAs in vitro, presumably through its KH domains [16,17]. Mutation of FMRP at position 304 abrogates its association with ribosomes and the mutated protein does not suppress translation.
It came as a surprise, therefore, that a series of recent papers [4,5,6] revealed that the RGG box, not the KH domains, is responsible for the binding of a specific subset of mRNAs to FMRP. RGG boxes are usually found within proteins in combination with other RNA-binding domains . Darnell et al.  identified which RNAs were preferentially bound by FMRP, by screening a pool of 96-mer RNAs containing 52 bases of random sequence. After multiple rounds of selection a limited set of RNAs was identified with a common motif of [DWGGN(0-2)]4 (where D is any nucleotide except C, W is U or A, and N is any nucleotide). At the same time, Schaeffer et al.  determined the minimal site within the FMR1 mRNA necessary for FMRP binding. They concluded that a 100-nucleotide fragment in the 3' coding region of the FMR1 gene is responsible for the specific binding of FMRP with its own mRNA, in contrast to earlier experiments in which FMRP was reported to bind to the 3' UTR of the FMR1 mRNA .
G-quartet-containing RNAs were also shown to be targets of FMRP in vivo. Using microarrays, Brown et al.  identified from total murine brain mRNAs associated with mRNPs that interact with actively translating ribosomes. FMRP-RNP particles were isolated from wild-type and knockout mouse brains and hybridized to microarrays containing 25,181 RNAs with sequences taken from the UniGene database of the National Center for Biotechnology Information  and 19,021 expressed sequence tags (ESTs) from the TIGR Gene Indices database . These experiments confirmed that FMRP binds approximately 4% of total brain mRNA. After rigorous selection, Brown et al.  obtained 432 different mRNAs specifically associated with the mouse FMRP-RNP complexes. Subsequently, comparing polyribosome fractions from normal human lymphoblastoid cells with those from cells isolated from fragile X patients on a microarray containing 35,000 human genes or ESTs, they identified 251 human mRNAs that show abnormal polyribosome profiles in fragile X patients. The set of genes whose mRNAs were found in the mRNP complexes in mRNAs from total mouse brain were compared with the set of human genes that gave an abnormal polyribosomal profile in the absence of the fragile X protein, using human orthologs of the mouse genes and the murine orthologs of the human genes, respectively. Of the genes found to be associated with the murine FMRP-RNP complexes, 14 were also identified in the abnormal polyribosomal fraction in the human study . A G-quartet structure was identified in 8 of these 14 genes. Thus, FMRP within cells binds preferentially to mRNAs that contain G-quartet structures.
Identifying the mRNA targets of FMRP in the cell may help us understand the clinical consequences of the absence of FMRP. Only around 0.01% of the sequences present in the UniGene database are predicted to have a G-quartet structure; thus only a minor fraction of all proteins may be transported through the cell by FMRP . Many of the predicted G-quartet-containing genes identified have a role in synaptogenesis, a process that is impaired in fragile X syndrome . The RNA that was the most enriched in the FMRP-RNP particles isolated from normal mouse brain, when compared with particles from fragile X mouse brain, codes for a guanine-nucleotide exchange factor related to the yeast secretion protein Sec-7 and is predicted to have a G-quartet structure . Several other members of GTPase pathways, including genes encoding oligophrenin-1 (a Rho-GTPase-activating protein), α GDI (a guanine nucleotide dissociation inhibitor) and the guanine-nucleotide exchange factor ARHGER6 have been found mutated in patients with non-specific mental retardation .
Of special interest are genes that have been isolated in more than one study. Examples of genes that were identified in the abnormal polyribosomal fractions in fragile X patients and that were present in the murine FMRP-RNP complexes are those encoding Munc13, a phorbol ester receptor involved in the maturation of Golgi vesicles and vesicle transport in neurons, and SAPAP4, which is involved in neuronal cell signaling . From the list of 14 mRNAs containing a G quartet that bind FMRP, as identified by Darnell et al. , 5 were also identified in the microarray studies by Brown et al. , including those encoding NAP22, which is present in axon terminals and dendritic spines and plays a role in maturation or maintenance of synapses, and the microtubule-associated protein MAP1B, which is involved in transport within neurons and is the human ortholog of the Drosophila futsch gene . Drosophila has only one homolog (dFXR) of the fragile X gene family (consisting of FMR1, FXR1 and FXR2). dFXR acts as a translational represser of futsch, thereby regulating the synaptic microtubule cytoskeleton. Association of dFXR with Futsch protein in vivo was demonstrated by immunoprecipitation. Flies with dFXR mutations display, among other symptoms, enlarged synaptic terminals, whereas double mutants deficient in both dFXR and Futsch have a normal phenotype, demonstrating the importance of the dFXR-Futsch interaction in flies. It remains to be resolved whether each of the identified FMR1 target genes is responsible for a small effect, or whether a few genes will turn out to be responsible for the majority of clinical symptoms of fragile X patients.
We also compared the G-quartet sequences of FMR1, FXR1 and FXR2 mRNAs (Figure 2b, 2c). Of the 31 guanines conserved between FMR1 genes in human, mouse and rat RNA , only 20 were detectable in FXR1 and 15 in FXR2. In FXR2 in particular, however, extra guanines at other positions may compensate for the absence of these consensus guanines. It therefore remains to be verified whether FXR1 and FXR2 mRNAs are able to form a G-quartet structure similar to that of FMR1 mRNA. Given the importance for the function of FMRP of interactions between the RGG box and the G-quartet structure, the differences in RGG-box sequence between FMRP, FXR1P and FXR2P could perhaps explain why FXR1P and FXR2P, which, unlike FMRP, are present in the mRNPs of fragile X patients, cannot fully compensate for the absence of the fragile X protein FMRP. Further characterization of the mRNA targets of the fragile X protein and possibly the identification of the mRNAs bound by FXR1P and FXR2P will aid our understanding of the complex mechanisms underlying fragile X syndrome.
Financial support for the fragile X research in Antwerp was obtained through grants of the Belgian National Fund for Scientific Research-Flanders (FWO), an Interuniversity Attaction Pole (IUAP-V) and the Fragile X Research Foundation (FRAXA).
- Kooy RF, Willemsen R, Oostra BA: Fragile X syndrome at the turn of the century. Mol Med Today. 2000, 6: 193-199. 10.1016/S1357-4310(00)01674-9.PubMedView ArticleGoogle Scholar
- Hagerman RJ: Physical and behavioral phenotype. In Fragile X Syndrome: Diagnosis, Treatment, and Research. Edited by Hagerman RJ, Cronister A. Baltimore: Johns Hopkins University;. 1996, 3-87.Google Scholar
- Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang F, et al: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991, 65: 905-914.PubMedView ArticleGoogle Scholar
- Darnell J, Jensen K, Jin P, Brown V, Warren ST, Darnell RB: Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell. 2001, 107: 489-499.PubMedView ArticleGoogle Scholar
- Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, Moine H: The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J. 2001, 20: 4803-4813. 10.1093/emboj/20.17.4803.PubMedPubMed CentralView ArticleGoogle Scholar
- Brown V, Jin P, Ceman S, Darnell J, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, et al: Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001, 107: 477-487.PubMedView ArticleGoogle Scholar
- Feng Y, Gutekunst C-A, Eberhart DE, Yi H, Warren ST, Hersch SM: Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci. 1997, 17: 1539-1547.PubMedGoogle Scholar
- Ashley CT, Wilkinson KD, Reines D, Warren ST: FMR-1 protein: conserved RNP family domains and selective RNA binding. Science. 1993, 262: 563-566.PubMedView ArticleGoogle Scholar
- Ceman S, Brown V, Warren ST: Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol. 1999, 19: 7925-7932.PubMedPubMed CentralView ArticleGoogle Scholar
- Willemsen R, Bontekoe C, Tamanini F, Galjaard H, Hoogeveen A, Oostra BA: Association of FMRP with ribosomal precursor particles in the nucleolus. Biochem Biophys Res Commun. 1996, 225: 27-33. 10.1006/bbrc.1996.1126.PubMedView ArticleGoogle Scholar
- Zhang Y, O'Connor JP, Siomi MC, Srinivasan S, Dutra A, Nussbaum RL, Dreyfuss G: The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J. 1995, 14: 5358-5366.PubMedPubMed CentralGoogle Scholar
- Tamanini F, Bontekoe C, Bakker CE, van Unen L, Anar B, Willemsen R, Yoshida M, Galjaard H, Oostra BA, Hoogeveen AT: Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum Mol Genet. 1999, 8: 863-869. 10.1093/hmg/8.5.863.PubMedView ArticleGoogle Scholar
- Eberhart DE, Malter HE, Feng Y, Warren ST: The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet. 1996, 5: 1083-1091. 10.1093/hmg/5.8.1083.PubMedView ArticleGoogle Scholar
- De Boulle K, Verkerk AJMH, Reyniers E, Vits L, Hendrickx J, van Roy B, van den Bos F, de Graaff E, Oostra BA, Willems PJ: A point mutation in the FMR1 gene associated with fragile X mental retardation. Nat Genet. 1993, 3: 31-35.PubMedView ArticleGoogle Scholar
- Tamanini F, Meijer N, Verheij C, Willems PJ, Galjaard H, Oostra BA, Hoogeveen AT: FMRP is associated to the ribosomes via RNA. Hum Mol Genet. 1996, 5: 809-813. 10.1093/hmg/5.6.809.PubMedView ArticleGoogle Scholar
- Laggerbauer B, Ostareck D, Keidel E-M, Ostareck-Lederer A, Fischer U: Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet. 2001, 10: 329-338. 10.1093/hmg/10.4.329.PubMedView ArticleGoogle Scholar
- Zhenzhong L, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y: The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 2001, 29: 2276-2283. 10.1093/nar/29.11.2276.View ArticleGoogle Scholar
- Burd CG, Dreyfuss G: Conserved functions and diversity of functions of RNA binding proteins. Science. 1994, 265: 615-621.PubMedView ArticleGoogle Scholar
- Brown V, Small K, Lakkis L, Feng Y, Gunter C, Wilkinson KD, Warren ST: Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein. J Biol Chem. 1998, 273: 15521-15527. 10.1074/jbc.273.25.15521.PubMedView ArticleGoogle Scholar
- Williamson JR, Raghuraman MK, Cech TR: Monovalent cation-induced structure of telomeric DNA: the G-quartet model. Cell. 1989, 59: 871-880.PubMedView ArticleGoogle Scholar
- UniGene. [http://www.ncbi.nlm.nih.gov/UniGene/index.html]
- TIGR Gene Indices. [http://www.tigr.org/tdb/tgi.shtml]
- Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP, Kooy F, Willems PJ, Cras P, Kozlowski PB, et al: Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet. 2001, 98: 161-167. 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B.PubMedView ArticleGoogle Scholar
- Antonarakis SE, Van Aelst L: Mind the GAP, Rho, Rab and GDI. Nat Genet. 1998, 19: 106-108. 10.1038/450.PubMedView ArticleGoogle Scholar
- Zhang YQ, Bailey AM, Matthies H-JG, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K: Drosophila fragile X-related gene regulates the MAP1B homolog futsch to control synaptic structure and function. Cell. 2001, 107: 591-603.PubMedView ArticleGoogle Scholar